Insider Selling: Castle Biosciences (NASDAQ:CSTL) COO Sells $585,247.28 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 14,888 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $39.31, for a total transaction of $585,247.28. Following the completion of the sale, the chief operating officer directly owned 12,323 shares of the company’s stock, valued at approximately $484,417.13. This represents a 54.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Castle Biosciences Stock Down 0.4%

Shares of CSTL opened at $39.44 on Monday. The business’s fifty day moving average price is $32.81 and its two-hundred day moving average price is $24.71. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -87.64 and a beta of 1.14. Castle Biosciences, Inc. has a 52 week low of $14.59 and a 52 week high of $40.61. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.32. The business had revenue of $80.55 million for the quarter, compared to analyst estimates of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. On average, analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Institutional Trading of Castle Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC grew its stake in Castle Biosciences by 139,100.0% in the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after acquiring an additional 1,391 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of Castle Biosciences in the 3rd quarter valued at approximately $35,000. CWM LLC increased its stake in Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after purchasing an additional 853 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Castle Biosciences by 63.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after buying an additional 976 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after buying an additional 2,648 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

CSTL has been the subject of a number of recent research reports. Robert W. Baird boosted their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 4th. Zacks Research upgraded shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Canaccord Genuity Group restated a “buy” rating and issued a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, September 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 15th. Finally, BTIG Research increased their target price on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Castle Biosciences presently has an average rating of “Moderate Buy” and an average target price of $39.14.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.